The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.
Tumour-induced bone disease is a common clinical feature of advanced breast and prostate cancer and is associated with considerable morbidity for the affected patients. Our understanding of the molecular mechanisms underlying the development of bone metastases is incomplete, but proteolytic enzymes are implicated in a number of processes involved in both bone metastasis and in normal bone turnover, including matrix degradation, cell migration, angiogenesis, tumour promotion and growth factor activation. Malignant as well as non-malignant cells in the primary and secondary sites express these enzymes, the activity of which may be regulated by soluble factors, cell- or matrix-associated components, as well as a number of cell signalling pathways. A number of secreted and cell surface-associated proteolytic enzymes are implicated in tumour-induced bone disease, including the matrix metalloproteinases, lysosomal cysteine proteinases and plasminogen activators. This review will introduce the role of proteolytic enzymes in normal bone turnover and give an overview of the studies in which their involvement and regulation in the development of bone metastases in breast and prostate cancer has been described. The results from trials involving protease inhibitors in clinical development will also be briefly discussed.
Woodward
Julia K L
JK
Academic Unit of Clinical Oncology, D Floor, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK.
Holen
Ingunn
I
Coleman
Robert E
RE
Buttle
David J
DJ
D000818:Animals; D001847:Bone Diseases / Q000201:enzymology* / Q000209:etiology*; D001943:Breast Neoplasms / Q000150:complications* / Q000201:enzymology*; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000150:complications* / Q000201:enzymology*; D015398:Signal Transduction
D010447:Peptide Hydrolases